 Raymond James has upgraded NGM Biopharmaceuticals Inc NASDAQ:NGM to Strong Buy from Outperform with a price target of 39, up from 27, almost 44 upside. Analyst Steven Seedhouse notes the validation of NGMs C3 antibody mechanism and the large potential opportunity for NGM621 in geographic atrophy GA. 